Introduction {#S1}
============

Adenomyosis is a common disease of the uterus in which endometrial epithelial cells and stromal fibroblasts abnormally are found in the myometrium, wherein they elicit hyperplasia and hypertrophy of surrounding smooth muscle cells ([@B4]). It occurs in 8--27% of reproductive age women ([@B16]) and results in a diffusely enlarged uterus, pelvic pain, heavy menstrual bleeding and infertility in those affected ([@B3]). Historically, definitive diagnosis was based on histological examination of hysterectomy specimens. Currently, decreased echogenicity or signal intensity on ultrasound and magnetic resonance imaging (MRI), respectively, is commonly used to diagnose adenomyosis which can occur in a diffuse pattern, as discrete adenomyomas, or cystic lesions in the uterine smooth muscle layer ([@B37]). As mechanisms underlying the pathogenesis and pathophysiology of adenomyosis are not well understood, therapies are inadequate to control symptoms or to facilitate successful pregnancy ([@B23]).

Disruption of the "inner myometrium," i.e., the normal boundary between the endometrial basal layer and the myometrium, has been postulated to underlie adenomyosis pathogenesis, with subsequent endometrial tissue and cells migrating into the adjacent smooth muscle compartment ([@B46]). As adenomyosis is more prevalent in women with previous cesarean section, it has been postulated that the endometrium invades a predisposed myometrium or a traumatized endometrial-myometrial interface during periods of regeneration, healing, and reepithelization ([@B6]). In addition, there also evidence of familial predisposition in which genetic, immunological and other factors are involved ([@B1]). Abnormal Müllerian and mesenchymal interactions during uterine development also may contribute to its pathogenesis, and tissue injury typically activates adult stem cells, which may establish endometrial lineage cells through disruption of endometrial stem/progenitor cell niches ([@B9]). Thus, both compartments (endometrium and myometrium) have been implicated in the pathogenesis of adenomyosis, although more research is required to understand, mechanistically, the initiation and progression of the disease. Herein, we focus on RNA methylation in both compartments.

Epigenetic modifications play an important role in regulation of human physiology and invasive diseases, among which DNA and RNA methylation are involved. While most studies have focused on the role of DNA methylation in the female reproductive system, less data are available regarding RNA methylation, especially in adenomyosis. N6-methyladenosine (m^6^A) is the most abundant modification on mRNAs ([@B59]). m^6^A provides dynamic regulation of the nucleation, splicing, translation and stability of mRNA molecules ([@B50]; [@B39]; [@B7]), thereby influencing fundamental biological and pathological processes such as proliferation, differentiation, cellular response to stress and tumorigenesis ([@B35]). The m^6^A modification regulators are classified into the three groups: writers, erasers and readers ([@B54]). "Writers" include the m^6^A methyltransferases that promote methylation of m^6^A. They are mainly composed of methyltransferase−like 3 (METTL3) and 14 (METTL14) and Wilms' tumor 1−associating protein (WTAP). Moreover, KIAA1429, zinc finger CCCH−type containing 13 (ZC3H13), METTL16 and RNA binding motif protein 15/15B (RBM15/15B) are also contribute to the RNA methylation ([@B52]; [@B58]). "Erasers" are demethylases which consist of fat mass and obesity−associated protein (FTO) and AlkB homolog 5 (ALKBH5). "Readers" are proteins that bind to the m^6^A site and promoting the function of m^6^A. They are predominantly in the YT521−B homology (YTH) protein family \[YTH domain family 1/2/3 (YTHDF1/2/3) and YTH domain containing 1/2 (YTHDC1/2)\], nuclear heterogeneous protein HNRNP family and IGF2BP protein family ([@B24]).

Previous studies indicated that m^6^A RNA methylation mediates cell proliferation and apoptosis in different cell types ([@B10]). Notably, increased proliferation and inhibition of cellular apoptosis are characteristics of the endometrium in women with adenomyosis ([@B22]). m^6^A also contributes to the epithelial-to-mesenchymal transition (EMT) of cancer cells ([@B21]) and EMT is considered to be a possible mechanism for the transfer of epithelial cell into the myometrium in adenomyosis patients ([@B13]). Moreover, m^6^A and its methylation regulators also regulate T cell activity ([@B53]) and vascular development, which is involved in endometrial dysfunction of adenomyosis patients ([@B34]; [@B2]). Thus, m^6^A RNA methylation may also play a role in the pathogenesis of adenomyosis.

m^6^A and its methylation regulators can also play roles in endometrial function in other settings. Liu et al. reported that about 70% of endometrial tumors exhibit reductions in m^6^A RNA methylation due to reduced *METTL3* expression. Moreover, m^6^A mRNA methylation is regarded as an oncogenic mechanism in endometrial cancer through regulation of AKT signaling ([@B25]). A previous study indicated that adenomyosis and type I endometrial cancer are linked to sex steroid action and exhibit gene expression profiling supporting a relationship between endometrial cancer and adenomyosis ([@B14]), and women with adenomyosis are at higher risks of endometrial cancer ([@B57]). The PI3K-AKT pathway, BCL2 apoptosis regulator and other factors are implicated in both adenomyosis and endometrial cancer ([@B38]). Thus, m^6^A RNA methylation may also contribute to endometrial dysfunction in women with adenomyosis.

Herein, we have investigated expression of m^6^A RNA methylation regulators in both endometrium and myometrium of women with versus without adenomyosis, providing a novel perspective and laying the foundation to elucidate underlying mechanisms of adenomyosis pathogenesis and pathophysiology.

Materials and Methods {#S2}
=====================

Gene Expression Profile {#S2.SS1}
-----------------------

We searched the associated gene expression profiles of the eutopic endometrium of adenomyosis patients in Gene Expression Omnibus (GEO) database^[1](#footnote1){ref-type="fn"}^, using the keywords "adenomyosis", "eutopic endometrium", and "Homo sapiens." We chose GSE78851 ([@B12]) for analysis (5 control and 3 adenomyosis). All the eight samples of eutopic endometrium are in proliferative phase and we retained gene expression datasets from the Affymetrix Human Gene 1.0 ST Array (HuGene-1_0-st) and detected gene expression changes in the eutopic endometrium between three patients with adenomyosis and 5 healthy women (control).

We further searched the gene expression profiles of the myometrium of women with adenomyosis in GEO database using "adenomyosis," "myometrium" and "Homo sapiens" and chose GSE7307 to investigate the mechanism of adenomyosis from the view of myometrium (10 women with adenomyosis versus 40 without adenomyosis). The gene expression was got from Affymetrix Human Genome U133 Plus 2.0 Array (HG-U133_Plus_2). We detected gene expression of myometrium between 10 women with adenomyosis (cases) and 40 without adenomyosis (controls).

Identifying Differentially Expressed Genes (DEGs) {#S2.SS2}
-------------------------------------------------

After downloading the GSE78851 and GSE7307 from GEO, the "impute" package of R software was used to impute the missing expression data while "limma" package was used to normalize the gene expression and identify the differentially expressed genes separately. The significant difference was defined as log FC \> 1 and *P* \< 0.05.

Selection of m^6^A RNA Methylation Regulators {#S2.SS3}
---------------------------------------------

We first assembled a list of eighteen m^6^A RNA methylation regulators from published literature and review ([@B54]), and then we restricted the list to sixteen genes with available RNA expression data separately from the GSE78851 and GSE7307 in GEO dataset. This yielded a total of sixteen m^6^A RNA methylation regulators. Then, we systematically compared the expression of these sixteen m^6^A RNA methylation regulators in the eutopic endometrium and myometrium of women with and without adenomyosis separately using Wilcox test in R software (^∗^*p* \< 0.05, ^∗∗^*p* \< 0.01, ^∗∗∗^*p* \< 0.001).

The Correlation Between m^6^A RNA Methylation Regulators and DEGs {#S2.SS4}
-----------------------------------------------------------------

Interactions among m^6^A RNA methylation regulators were analyzed using the STRING^[2](#footnote2){ref-type="fn"}^. Moreover, the correlation between m^6^A RNA methylation regulators and highly enriched Gene ontology (GO) terms related DEGs were identified using Spearman correlation in the "Corrplot" package of R software. *p* \< 0.001 was considered as significantly correlated to each other.

Weighted Gene Co-expression Network Analysis (WGCNA) {#S2.SS5}
----------------------------------------------------

To verify the potential relationship and the co-expression genes of m^6^A RNA methylation regulators that were differentially expressed in the women with and without adenomyosis, we used another method to analyze the DEGs in the eutopic endometrium and myometrium separately. WGCNA assigns a connection weight to each gene pair in the network, being more meaningful compared to traditional methods that use binary information. Thus, WGCNA can be used to find modules of highly correlated genes and identify candidate target genes ([@B18]). We used WGCNA to analyze the DEGs and identified the relationship between m^6^A RNA methylation regulators and the potential target genes of m^6^A RNA methylation regulators in the eutopic endometrium and myometrium separately.

Enrichment Analysis {#S2.SS6}
-------------------

GO analysis was used to identify the possible molecular function and visualize the potential biological meaning behind DEGs, whereas Kyoto Encyclopedia of Genes and Genomes (KEGG) was to analyze the potential functions of these genes. The gene ID was set using the "org.Hs.eg.db" of R software, and then GO and KEGG pathway enrichment analyses were performed with "clusterProfiler." *p* \< 0.05 was identified as significant.

Clinical Sample Collection {#S2.SS7}
--------------------------

Clinical symptoms and histologic evaluation of hysterectomy specimens identified samples from cases and controls (latter had hysterectomies due to uterine fibroids or dysmenorrhea). Full thickness uterine specimens (including endometrium, inner myometrium and outer myometrium) were collected and stored in OCT at −80°C. All participants (*n* = 9 cases; *n* = 9 controls) were in the proliferative phase of the cycle, confirmed by endometrial histology ([@B33]) and serum estrogen (E~2~), progesterone levels (P~4~). All participants were documented to be not pregnant and had not received hormonal or gonadotropin-releasing hormone agonist (GnRHa) therapies for at least 3 months prior to tissue sampling. 6 cases and 6 controls were used for the detection of the percentage of m^6^A in total RNA and validation of real-time polymerase chain reaction (qRT-PCR) while the rest of the cases and controls samples (3 for each group) were used for immunohistochemistry (IHC) and m^6^A quantification of only mRNA. The clinical samples were collected from the Endometrial Tissue and DNA Bank at the University of California, San Francisco under an approved human subjects protection protocol (IRB \# 10-02786), after written informed consent of all participants.

Hematoxylin and Eosin (H&E) Stain {#S2.SS8}
---------------------------------

The full thickness uterine tissue was embedded in OCT and stored at −80°C. Five μm-thick tissue frozen sections were prepared and then OCT blocks were returned to −80°C and stored at this temperature until further use. Slides were brought to room temperature and left for at least an hour prior to fixing the tissue in 100% ethanol for 10 min. Then, the slides were stained in hematoxylin for 7 min and differentiated by hydrochloric acid for 30 s. Finally, the sections were incubated in eosin for 1 min before covering the slide and visualizing using a microscope (Zeiss, Oberkochen, Germany).

qRT-PCR {#S2.SS9}
-------

The endometrium and myometrium of OCT blocks were separated on ice according to H&E stain. We chose the myometrium close to the interface between the endometrium and myometrium, so that most of myometrial samples were mainly inner myometrium. Total RNA from endometrium and myometrium was extracted, separately, using an RNA isolation kit (Macherey-Nagel, Bethlehem, PA, United States) and reversely transcribed into cDNA (TAKARA, Dalian, China). The mRNA expression of target genes was detected using qRT-PCR. Results were analyzed by ΔΔCt method. The ratio of the target gene over β*-Actin* was calculated as the target mRNA level. The primer sequences used for targeting genes are shown in [Supplementary Table](#SM1){ref-type="supplementary-material"}.

Total m^6^A RNA Methylation Assay {#S2.SS10}
---------------------------------

The m^6^A RNA Methylation Assay Kit (Abcam, Cambridge, United Kingdom) was used to evaluate the content of m^6^A in total RNA as protocol. Total RNA was bound to the strip wells using an RNA high binding solution provided by the manufacturer. Briefly, 200 ng total RNA were coated on each assay well, followed by specific capture with N6-methyladenosine antibody and the detection antibody. Then the detected signal was enhanced and quantified colorimetrically by reading the absorbance in a microplate spectrophotometer at a wavelength of 450 nm. The amount of m^6^A is proportional to the OD intensity measured. Finally, calculations using OD450 values were performed based on the standard curve to get the final content of m^6^A level in total RNA.

IHC {#S2.SS11}
---

Five μm-thick tissue frozen sections were prepared using OCT blocks of full thickness uterine tissue. Slides were rehydrated and then blocked using blocking buffer for 1 h at room temperature. Heat-mediated antigen retrieval was carried out with 10 mM sodium citrate, 0.05% Tween 20, pH 6, and then slides were incubated in anti-METTL3 antibody (1:200 dilution; Proteintech, Wuhan, China) overnight at 4°C. After being washed with PBS, the slides were processed with the secondary antibody (1:400) for 1 h at room temperature, and then the color reaction was visualized by exposure to diaminobenzidine (DAB). Slides were counterstained with hematoxylin and dehydrated through graded alcohols and xylene before visualizing using a microscope (Zeiss). Staining was assessed using Image J.

m^6^A Quantification by Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) {#S2.SS12}
---------------------------------------------------------------------------------

RNA m^6^A quantification by LC-MS/MS was performed as described previously ([@B26]). In brief, total RNA from the endometrium and myometrium of women with and without adenomyosis was isolated using TRIzol reagent (Invitrogen, CA, United States), and polyadenylated RNAs were extracted by oligo d(T)25 magnetic beads (NEB, Ipswich, MA, United States), followed by removal of rRNA with RiboMinus Eukaryote Kit (Ambion, Austin, TX, United States). 200 ng mRNA were digested by nuclease P1 (1 U, Sigma-Aldrich, St. Louis, MO, United States) in 20 μL buffer which contained 25 mM NaCl, 2.5 mM ZnCl2 for 2 h at 37°C. After an additional incubation at 37°C for 2 h, the solution was centrifuged at 13000 rpm for 10 min at 4°C, and 10 μL of the solution was injected into LC-MS/MS. Quantification was performed by comparison with the standard curve obtained from pure nucleoside standards. The ratio of m^6^A to A in polyadenylated RNAs was calculated based on the calculated concentrations.

Statistical Analysis {#S2.SS13}
--------------------

Results are presented as mean ± SEM. The m^6^A level and qRT-PCR quantification of target genes between women with and without adenomyosis were analyzed in unpaired Student's *t*-test with SPSS software (IBM, New York, NY, United States). Statistical significance is shown as ^∗^*P* \< 0.05, ^∗∗^*P* \< 0.01, or ^∗∗∗^*P* \< 0.001.

Results {#S3}
=======

Endometrium {#S3.SS1}
-----------

### m^6^A RNA Methylation Regulators Are Decreased in Endometrium of Women With Adenomyosis {#S3.SS1.SSS1}

From the analysis of the gene expression profile of GSE78851, we found that *METTL3*, *ZC3H13*, *FTO*, and *YTHDC1* were all significantly decreased in the eutopic endometrium of adenomyosis patients versus controls ([Figure 1A](#F1){ref-type="fig"}). METTL3 is a "writer," and ZC3H13 aids in the RNA methylation process; while FTO belongs to the "erasers," and YTHDC1 is a "reader" ([@B54]). Thus, we pursued whether m^6^A levels are regulated by the above-mentioned factors in cases versus controls. Specifically, we examined m^6^A modification-related interactions and correlations among the 16 m^6^A RNA methylation regulators. STRING database analysis suggested that *METTL3* and *WTAP* are "hub" genes of the m^6^A RNA methylation regulators, as both interact with 12 m^6^A RNA methylation regulators (interaction score ≥ 0.7) ([Figures 1B,C](#F1){ref-type="fig"}). Moreover, the expression of *METTL3* was also significantly correlated to expression of all other differentially expressed m^6^A RNA methylation regulators in endometrium of cases versus controls, including *YTHDC1*, *FTO*, and *ZC3H13* ([Figure 1D](#F1){ref-type="fig"}, Spearman R) without any change in the expression of *WATP*. Therefore, *METTL3* is a prime candidate as the "hub" gene of m^6^A RNA methylation regulators involved in endometrial dysfunction in the setting of adenomyosis.

![The expression and interaction of m^6^A RNA methylation regulators in the eutopic endometrium of women with and without adenomyosis. **(A)** The expression levels of sixteen m^6^A RNA methylation regulators in the eutopic endometrium. **(B)** The m^6^A modification-related interactions among the 16 m^6^A RNA methylation regulators. **(C)** The interaction counts of 16 m^6^A RNA methylation regulators. **(D)** Spearman correlation analysis of the 16 m^6^A modification regulators.](fgene-11-00716-g001){#F1}

### DEGs Associated With Endometrium of Adenomyosis Women and Function Analyses {#S3.SS1.SSS2}

Using "limma" package, we analyzed GSE78851 and found 791 transcripts differentially expressed (191 up regulated and 600 down regulated) in endometrium of cases versus controls ([Figure 2A](#F2){ref-type="fig"}). Biological functions of these DEGs were identified using GO and KEGG enrichment. With GO, enrichment was noted in "epithelial cell proliferation," "regulation of fibroblast proliferation," "regulation of cell migration," "cell-substrate adherens junction," "regulation of Wnt signaling pathway" and other biological processes were highly enriched in DEGs \[FDR (adjust *P*) \< 0.05\]. In addition, other significantly enriched biological processes were related to m^6^A function, including "RNA splicing," "regulation of mRNA stability," "translation preinitiation complex" and "structural constituent of ribosome" ([Figure 2B](#F2){ref-type="fig"}).

![The expression, functional enrichment of DEGs in the eutopic endometrium of women with and without adenomyosis. **(A)** The differentially expressed transcripts in the eutopic endometrium of adenomyosis patients versus controls (3 adenomyosis patients and 5 controls). **(B)** Functional annotation of the DEGs of eutopic endometrium using GO terms of biological processes (upper) and KEGG pathway (lower).](fgene-11-00716-g002){#F2}

### WGCNA and Correlation Analysis to Identify Co-expression and Possible Target Genes of m^6^A RNA Methylation Regulators in Endometrium of Women With Adenomyosis {#S3.SS1.SSS3}

As previously described, *METTL3* is considered as the "hub" m^6^A RNA methylation regulator. Accordingly, further exploration of the correlation between the 217 DEGs from these highly enriched GO terms and the expression of *METTL3* was performed to clarify a possible role of m^6^A RNA methylation regulators in the dysfunction of endometrium of women with adenomyosis ([Figure 3A](#F3){ref-type="fig"}). We found 67 genes were significantly correlated to the expression of *METTL3*. Nine of these were involved in "epithelial cell proliferation," 2 were involved in "negative regulation of cell migration" and 2 contributed to "negative regulation of cell cycle phase transition."

![The correlation analysis and WGCNA of DEGs in the eutopic endometrium. **(A)** The Spearman correlation analysis of the m^6^A modification regulators and the DEGs enriched in the GO terms that related to eutopic endometrium dysfunction of adenomyosis. "X" *p* \> 0.001, Red line clarified that correlation between METTL3 and other DEGs. **(B)** WGCNA of DEGs in the eutopic endometrium of women with adenomyosis versus without. Red arrow revealed the module that the m^6^A RNA methylation regulators belong to. **(C)** The co-expressed genes of four differential expressed m^6^A RNA methylation regulators using WGCNA analysis (threshold = 0.8).](fgene-11-00716-g003){#F3}

WGCNA was used to further identify target genes of differentially expressed m^6^A RNA methylation regulators in endometrium of cases versus controls. Firstly, we found all differentially expressed m^6^A RNA methylation regulators (METTL3, FTO, ZC3H13, and YTHDC1) belong to the "turquoise" module ([Figure 3B](#F3){ref-type="fig"}), demonstrating their close relationship to each other. Secondly, genes that were significantly co-expressed or correlated to the four differentially expressed m^6^A RNA methylation regulators were identified, and the network is shown in [Figure 3C](#F3){ref-type="fig"}. Combining the Spearman correlation between *METTL3* and DEGs and WGCNA results, a total of 19 co-expressed genes were found, which may be target genes of m^6^A RNA methylation regulators in eutopic endometrium of cases versus controls (threshold = 0.8) ([Table 1](#T1){ref-type="table"}).

###### 

The potential target genes of differential expressed m^6^A RNA methylation regulators in the eutopic endometrium.

  **Gene name**   **GO terms**
  --------------- ----------------------------------------------------------------------
  CNN3            Cell-substrate adherens junction
  RPS14           Cell-substrate adherens junction, structural constituent of ribosome
  RPS16           Cell-substrate adherens junction, structural constituent of ribosome
  RPS25           Cell-substrate adherens junction, structural constituent of ribosome
  RPS27A          cell-substrate adherens junction, structural constituent of ribosome
  RPL11           Cytoplasmic translation
  IGF1            Epithelial cell proliferation
  DDT             negative regulation of cell migration
  PSMB1           Regulation of mRNA stability
  RBX1            Regulation of Wnt signaling pathway
  SF3B6           RNA splicing
  RPL14           Structural constituent of ribosome
  RPL23A          Structural constituent of ribosome
  RPL24           Structural constituent of ribosome
  RPL30           Structural constituent of ribosome
  RPL38           Structural constituent of ribosome
  RPL39P5         Structural constituent of ribosome
  RPL7            Structural constituent of ribosome
  RPLP0           Structural constituent of ribosome

### Validation of the Total m^6^A Level, m^6^A RNA Methylation Regulators and Possible Target Genes in Endometrium of Women With Adenomyosis {#S3.SS1.SSS4}

After combing the results from the bioinformatics analyses, m^6^A levels and *METTL3* were considered as likely functional regulators in endometrium of women with adenomyosis. To validate this hypothesis, we studied total m^6^A levels and the relative expression of m^6^A RNA methylation regulators in endometrium from a cohort of women with adenomyosis (*n* = 6) and controls (*n* = 6) -- all in the proliferative phase of the menstrual cycle. The percentage of m^6^A content in total RNA of endometrium was significantly reduced ([Figure 4A](#F4){ref-type="fig"}), while a trend for lower amounts of m^6^A was detected in polyadenylated RNA of cases versus controls ([Supplementary Figure 1A](#FS1){ref-type="supplementary-material"}), similar to endometrial cancer ([@B25]). Moreover, *METTL3*, and *YTHDC1* mRNA were also decreased ([Figure 4B](#F4){ref-type="fig"}). We also detected METTL3 protein in endometrium via IHC. We found high expression of METTL3 protein both in the glands and stroma of control endometrium ([Supplementary Figure 2A](#FS2){ref-type="supplementary-material"}). The protein level of METTL3 was significantly decreased in the endometrium of adenomyosis patients when compared with control (*p* = 0.034), consistent with its mRNA level.

![The total m^6^A level and qRT-PCR validation of bioinformatics data in eutopic endometrium of women with and without adenomyosis. **(A)** m^6^A% content in total RNA in the eutopic endometrium of women with and without adenomyosis. **(B)** The expression of *METTL3*, *ZC3H13*, *YTHDC1* mRNA level in the eutopic endometrium. **(C)** The expression of *IGF1, DDT*, and *CNN3* mRNA level in the eutopic endometrium. *n* = 6 for each group. \**p* \< 0.05.](fgene-11-00716-g004){#F4}

Furthermore, we verified the potential target genes of differentially expressed m^6^A RNA methylation regulators identified above. Messenger RNA for *insulin−like growth factor−1 (IGF1)*, the key regulator of the epithelial proliferation and the AKT pathway ([@B44]; [@B32]), was significantly increased in cases versus controls. Furthermore, *D-dopachrome tautomerase (DDT)*, works as a gene responsible for cell migration and cell proliferation ([@B31]), were also significantly highly expressed in cases versus controls, without any change in *Calponin 3 (CNN3)* ([Figure 4C](#F4){ref-type="fig"}).

Myometrium {#S3.SS2}
----------

### Expression of m^6^A RNA Methylation Regulators and Functional Analysis of DEGs in Myometrium of Women With Adenomyosis {#S3.SS2.SSS1}

Gene expression profiles of myometrium of women with and without adenomyosis were mined from GSE7307. Gene expression of the myometrium of adenomyosis group (*n* = 10) was compared to the control group (*n* = 40) comprised of myometrial samples without adenomyosis, endometriosis and/or cancer. The comparison identified 563 DEGs, of which 278 genes were down regulated, and 285 genes were upregulated from cases versus controls. Expression of 16 m^6^A RNA methylation regulators is shown in [Figure 5A](#F5){ref-type="fig"}, and 11 of them were significantly differentially expressed in the myometrium of adenomyosis patients including *RBM15/15B*, *ALKBH5*, *FTO*, *YTHDF1/2*, *KIAA1429*, *HNRNPC*, *METTL3*, *ZC3H13*, and *YTHDC2* ([Figure 5A](#F5){ref-type="fig"}).

![The expression of m^6^A RNA methylation regulators and the functional enrichment of DEGs in the myometrium of women with and without adenomyosis. **(A)** The expression levels of sixteen m^6^A RNA methylation regulators in the myometrium (10 women with adenomyosis and 40 without adenomyosis). **(B)** Functional enrichment of the DEGs of myometrium using GO terms of biological processes (upper) and KEGG pathway (lower).](fgene-11-00716-g005){#F5}

Functional analysis revealed that "muscle tissue development," "cell-cell adhesion via plasma-membrane adhesion molecules," "positive regulation of epithelial cell differentiation," "muscle contraction," "neutrophil activation involved in immune response," "connective tissue development" and other biological processes were highly enriched in DEGs in myometrium of cases versus controls ([Figure 5B](#F5){ref-type="fig"}).

### WGCNA and Correlation Analysis to Identify Potential Target Genes of m^6^A RNA Methylation Regulators in the Myometrium {#S3.SS2.SSS2}

Different from endometrium, 13 of 16 m^6^A RNA methylation regulators in myometrium were significantly correlated to each other, and most of them were down regulated in adenomyosis patients using Spearman correlation ([Figures 5A](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}). Additionally, the 13 m^6^A RNA methylation regulators were all attributed to the "blue" module using WGCNA ([Supplementary Figure 3](#FS3){ref-type="supplementary-material"}). Thus, the 13 m^6^A RNA methylation regulators (*RBM15/15B*, *YTHDF1*, *WTAP*, *KIAA1429*, *ZC3H13*, *YTHDC2*, *METTL3*, *METTL14*, *YTHDC1*, *ALKBH5*, and *FTO*) were identified as a "cluster" of m^6^A methylation regulators in the myometrium of women.

![The Spearman correlation between m^6^A RNA methylation regulators and the DEGs of myometrium enriched in the GO terms that related to myometrium dysfunction of adenomyosis patients. "X" *p* \> 0.001, Red line clarified that correlation between the 13 m^6^A regulation "cluster" and other DEGs.](fgene-11-00716-g006){#F6}

We analyzed the correlation between the 107 DEGs in these highly enriched biological processes in myometrium of women with adenomyosis and controls and m^6^A regulator "cluster" to clarify potential mechanisms underlying regulation of m^6^A RNA methylation regulators in the setting of disease. Genes that significantly correlated to the expression of the "m^6^A regulator cluster" were identified as potential target genes of m^6^A RNA methylation regulators in the myometrium. Fifteen genes were identified, 4 of which were involved in "muscle contraction", 3 with "cell-cell adhesion" and 2 genes were involved in "neutrophil activation involved in immune response" ([Table 2](#T2){ref-type="table"}; [Figure 6](#F6){ref-type="fig"}).

###### 

The DEGs from high enriched GO terms that are significantly correlated to m^6^A RNA methylation regulators cluster in the myometrium.

  **Gene name**   **GO terms**
  --------------- ------------------------------------------------------------
  CDH3            Cell--cell adhesion mediated by cadherin
  IGSF9B          Cell--cell adhesion via plasma-membrane adhesion molecules
  ADGRL3          Cell--cell adhesion via plasma-membrane adhesion molecules
  SCN4B           Muscle contraction
  TNNC2           Muscle contraction
  TMOD2           Muscle contraction
  GRIP2           Muscle contraction
  ATF3            Muscle organ development
  EGR2            Muscle organ development
  ATP8B4          Neutrophil activation involved in immune response
  PLAC8           Neutrophil activation involved in immune response
  LIF             Positive regulation of epithelial cell differentiation
  FGF7            Positive regulation of epithelial cell proliferation
  HYAL1           Positive regulation of epithelial cell proliferation
  PLXNB3          Positive regulation of epithelial cell proliferation

### Validation of the Total m^6^A Level, m^6^A RNA Methylation Regulators and Possible Downstream Factors in the Myometrium of Women With Adenomyosis {#S3.SS2.SSS3}

Equivalent to the eutopic endometrium, the m^6^A% content in total RNA of myometrium was also significantly reduced ([Figure 7A](#F7){ref-type="fig"}) while a decreased tendency of m^6^A% was detected in polyadenylated RNA of women with adenomyosis compared with controls ([Supplementary Figure 1B](#FS1){ref-type="supplementary-material"}). In addition, expression of *METTL3* and *FTO* mRNA was decreased without changes in *METTL14* and *ALKBH5* ([Figure 7B](#F7){ref-type="fig"}). The protein level of METTL3 appeared lower in myometrium of women with adenomyosis compared with controls (*p* = 0.198) ([Supplementary Figure 2B](#FS2){ref-type="supplementary-material"}). Expression of identified genes that were significantly correlated with the m^6^A regulator "cluster" in the myometrium was also verified. As a key molecule in cell-cell adhesion and EMT ([@B43]), *cadherin 3 (CDH3)* mRNA was significantly increased in adenomyosis patients. Additionally, *sodium channel*β*-subunit 4 (SCN4B)* mRNA was decreased, suggesting possible regulation of m^6^A RNA methylation regulators to cell adhesion in adenomyosis. Finally, *placenta-specific protein 8 (PLAC8)* mRNA was also increased in the myometrium of adenomyosis patients, indicating the role of immune response in the myometrium of women with adenomyosis ([@B15]; [Figure 7C](#F7){ref-type="fig"}).

![The total m^6^A level and qRT-PCR validation of bioinformation data in myometrium of women with and without adenomyosis. **(A)** m^6^A% content in total RNA in the myometrium of adenomyosis and control patients. **(B)** The expression of *METTL3*, *METTL14*, *ALKBH5*, *FTO* mRNA level in the myometrium. **(C)** The expression of *CDH3, SCN4B, PLAC8*, and *EGR2* mRNA level in the myometrium. *n* = 6 for each group. \**p* \< 0.05.](fgene-11-00716-g007){#F7}

Discussion {#S4}
==========

Both Endometrium and Myometrium Dysfunction Contribute to the Pathogenesis of Adenomyosis {#S4.SS1}
-----------------------------------------------------------------------------------------

Adenomyosis is a disease with unknown pathogenesis, and diagnostics rely on the utilization of imaging techniques based on differences in the appearance of smooth muscle, particularly the inner myometrium ([@B16]). One hypothesis of the pathogenesis of adenomyosis is that the adenomyosis lesions originate from invaginating endometrium basalis, due to the similarities between these tissues. Thus, the disruption of the normal boundary (inner myometrium) may result in invasion of endometrial cells into the myometrium, inducing myocyte hypertrophy ([@B46]). At the same time, *in vitro* studies have demonstrated that myocytes from adenomyosis enhance invasion of endometrial stromal cells, compared to normal myocytes. Moreover, some studies have reported misexpression of estrogen receptor (ER) and progesterone receptor (PR) in the inner myometrium, including increased ER-β and decreased PR-A and PR-B ([@B29]). While myometrial dysfunction in the pathogenesis of adenomyosis has been proposed ([@B30]), other studies demonstrate that disruption of the myometrium does not necessarily result in adenomyosis ([@B28]). With regard to the endometrium, there is increased invasiveness of the E-cadherin negative epithelial cells ([@B8]; [@B2]; [@B5]) and abnormal estrogen. Thus, adenomyosis appears to be a disease of both the myometrial and endometrial compartments, although further research is needed to understand mechanisms contributing to the pathogenesis and pathophysiology of this disorder.

m^6^A RNA Methylation Regulators Are Involved in Eutopic Endometrium Dysfunction of Women With Adenomyosis {#S4.SS2}
----------------------------------------------------------------------------------------------------------

RNA methylation, especially m^6^A, contributes to biological processes such as cell proliferation, immunology ([@B53]; [@B60]), tumorigenesis ([@B7]) and tissue development ([@B17]; [@B55]; [@B11]), all of which may be involved in the pathogenesis of adenomyosis. Moreover, reduced *METTL3* and m^6^A level have been detected in endometrial cancer, which shares some characteristics with adenomyosis.

*METTL3* expression was significantly decreased in the endometrium of adenomyosis patients with reduced total m^6^A levels, similar to those in endometrial cancer ([@B25]). As a result, reduced m^6^A may contribute to the endometrial dysfunction in the setting of adenomyosis via different functional pathways. We found that DEGs were involved in epithelial cell proliferation, vasculature development, cell migration and macrophage migration, processes consistent with recent RNA-seq data of the endometrium in women with adenomyosis ([@B56]). Moreover, Benagiano and Brosens have also suggested that some of enriched biological processes (e.g., increase angiogenesis, proliferation of endometrium and Wnt signaling pathway) are involved in the pathogenesis of adenomyosis ([@B2]). We further investigated the correlation and co-expression among the DEGs in these biological processes and *METTL3*, the "hub" gene of m^6^A RNA methylation regulators in the endometrium, suggesting the possible target genes of *METTL3* and m^6^A regulation.

IGF1 is an effective growth factor in disease progression and plays an important role in cellular growth, proliferation, invasion, and angiogenesis of several tissues. Our study revealed that *IGF1* was differentially expressed in the microarray analysis and was significantly correlated with expression of *METTL3* in the endometrium of adenomyosis patients. Previous study demonstrated that the decreased METTL3 and m^6^A RNA methylation level can promote the cell proliferation through the AKT pathway in the endometrium, while IGF1 contributes to the regulation of AKT ([@B25]). Thus, combining the bioinformatic analyses herein with data from the literature, we propose that *METTL3* regulates m^6^A and contributes to increased expression of *IGF1*, which further promotes cell proliferation and invasion of endometrial cells into the myometrium via AKT pathway. However, the mechanism underlying the regulation of METTL3 and m^6^A to IGF1 and AKT pathway still need to be further investigated.

EMT, induced in the basal endometrium by high levels of estrogen, resulted in invagination of endometrium into myometrium, thereby playing an important role in the pathogenesis of adenomyosis ([@B13]). Herein, in our data analysis we found the decreased expression of *cadherin 1*(E-cadherin), a marker of the epithelial cell and EMT. Wnt pathway activation induces EMT in several tissues ([@B45]); we found that *WNT5A* mRNA was differentially expressed in the endometrium of adenomyosis patients. *WNT5A* may contribute to the pathogenesis of adenomyosis through proliferation of epithelial and fibroblast cells and regulation of vasculature development. However, expression of *WNT5A* was not correlated to *METTL3* in endometrium, suggesting it is not under the control of m^6^A RNA methylation regulators. Beside Wnt signaling, previous studies demonstrated that METTL3 and m^6^A levels contribute to EMT in lung cancer ([@B51]). IGF1 upregulates components of the Wnt signaling pathway and promotes EMT, and it is co-expressed with METTL3 ([@B47]). Thus, increased *IGF1* in eutopic endometrium may mediate the regulation of METTL3 and contribute to the endometrial dysfunction in adenomyosis women through EMT.

Besides of EMT, multipotent stem cells that travel from the endometrium to the myometrium and subsequently differentiate into lineage epithelial and/or stromal fibroblasts provide another possibility for adenomyosis pathogenesis. METTL3 and m^6^A can also contribute to the differentiation of stem cells in different tissues, indicating another possible role of m^6^A and METTL3 in adenomyosis ([@B19]).

DDT is the a member of the macrophage migration inhibitory factor (MIF) protein superfamily ([@B31]) and is involved in regulation of cell migration and other biological processes in various tumors. Previous studies found that DDT and MIF are involved in proliferation, migration, and invasion of cervical cancer ([@B49]). Moreover, MIF contributes to development of endometriosis, and MIF expression is increased in the endometrium of adenomyosis women ([@B36]). In our data analysis results, we also found MIF to be significantly differentially expressed in the endometrium of women with adenomyosis. However, its correlation to *METTL3* and other m^6^A RNA methylation regulators was not significant. Thus, MIF may be involved in endometrial dysfunction of women with adenomyosis, but not under the regulation of m^6^A RNA methylation regulators. DDT is significantly co-expressed with m^6^A RNA methylation regulators and binds to MIF cell surface receptor, inducing similar cell signaling and effector functions. Thus, the increased *DDT* mRNA in the endometrium of adenomyosis patients could mediate regulation of m^6^A RNA methylation regulators relevant to cell migration of endometrium in the setting of adenomyosis.

m^6^A RNA Methylation Regulators Play Roles in the Myometrium Dysfunction of Women With Adenomyosis {#S4.SS3}
---------------------------------------------------------------------------------------------------

Our study also revealed decreased m^6^A content and 11 differentially expressed m^6^A RNA methylation regulators in myometrium of adenomyosis patients, providing a possible mechanism for myometrial dysfunction of adenomyosis. Moreover, downstream factors of m^6^A regulation may participate.

While immune activation is mainly observed in endometrium of women with adenomyosis, e.g., increased endometrial macrophages and autoantibodies such as anti-phosphatidylinositol IgG, anti-phosphatidylglycerol IgG ([@B34]), immune dysregulation may also occur in the myometrium of affected women. m^6^A has been shown to be involved in immune regulation ([@B48]), and our functional enrichment analysis of DEGs in myometrium herein highlights neutrophil activation in cases versus controls. Additionally, PLAC8, a multi-faceted protein involved in various cellular physical processes (such as the regulation of immunity, cell differentiation and apoptosis) ([@B20]), was also increased in the myometrium in adenomyosis patients and was closely related to m^6^A RNA methylation regulator "cluster." Thus, the myometrium has processes in place for immune cell response in the setting of adenomyosis, associated with m^6^A RNA methylation regulators.

SCN4B is the β-subunit of voltage-gated sodium channels (VGSCs), required for generation of action potentials in excitable cells, and it also functions in cell--cell adhesion ([@B42]). Expression of *SCN4B* has been detected in the longitudinal smooth muscle layer of rat myometrium ([@B40]), suggesting its role in myometrial homeostasis and contractility. Functional enrichment analysis of myometrial DEGs in our study identified SCN4B associated with "muscle contraction" and was also significantly correlated with expression of the m^6^A regulator "cluster." Moreover, expression of *SCN4B* mRNA was decreased in myometrium of adenomyosis patients, as were *METTL3* and *FTO*. Thus, m^6^A RNA methylation regulators may regulate cell adhesion through *SCN4B*, further contributing to adenomyosis development.

In the myometrium, the GO enrichment of DEGs revealed that *WNT5A* was decreased and was involved in "the connective tissue development," "muscle development" and other processes. However, it was also not correlated to the m^6^A RNA methylation regulators "cluster" herein. Thus, *WNT5A* may contribute to the pathogenesis of adenomyosis but is not regulated through the regulation of m^6^A RNA methylation regulators.

Strengths and Limitations {#S4.SS4}
-------------------------

The strengths of this study include mining publicly available databases with abundant gene expression on human endometrium and myometrium separately from women with and without adenomyosis. Also, the endometrial and myometrial specimens used for validation were obtained using standard operating procedures (SOPs) from the UCSF NIH Human Endometrial Tissue and DNA Bank with well annotated clinical data in our RedCap Database ([@B41]^[3](#footnote3){ref-type="fn"}^). Moreover, our study is the first to propose possible involvement of RNA methylation in the pathogenesis of adenomyosis. It thus provides a novel paradigm needing subsequent mechanistic validation. It also potentially opens new avenues for novel targeted therapeutic approaches for symptoms associated with this disorder.

The limitations of our study were that the roles of the m^6^A RNA methylation regulators and their downstream factors in adenomyosis was deduced from gene expression profile analysis. Mechanisms underlying a role for m^6^A RNA methylation regulation still needs to be demonstrated through animal and *in vitro* experiments. In addition, although we did the validation using clinical samples, the sample size was limited, and the protein levels of target genes still needed to be detected. Other limitations include: the type of adenomyosis lesions (diffuse, adenomyoma, or cystic), clinical data, and cycle phase of subjects of the myometrium samples used in the data reported in the GEO database are not known. Notably, our validation approach used myometrium solely from the proliferative phase of the cycle, and previous studies have demonstrated expression of some genes in myometrium in adenomyosis patients do not vary with cycle phase ([@B27]), giving some mitigation to this limitation.

Summary and Conclusion {#S5}
======================

Herein, we investigated gene expression and the interactome of m^6^A RNA methylation regulators and total m^6^A levels in adenomyosis patients. Decreased *METTL3* and total m^6^A levels in endometrium of adenomyosis patients may contribute to cell proliferation and invasion through *IGF1* and *DDT*. The RNA methylation levels of specific and target genes such as *IGF1*, *DDT, PLAC8*, and *SCN4B* remain to be investigated using methods such as methylated RNA immunoprecipitation sequencing (MeRIP-seq) and MeRIP-qPCR. Furthermore, in the myometrium, m^6^A RNA methylation regulators work as a cluster and play roles in cell adhesion, muscle contraction and immune response. In conclusion, m^6^A RNA methylation regulators may be involved the pathogenesis of adenomyosis through aberrant expression and actions in both the uterine endometrium and myometrium.
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m^6^A% content in the polyadenylated RNA of eutopic endometrium and myometrium of women with and without adenomyosis. **(A)** Eutopic endometrium; **(B)** Myometrium. *n* = 3 samples were analyzed in each group.
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The IHC of METTL3 in the endometrium and myometrium of women with and without adenomyosis. **(A)** The endometrium of women with (right panel) and without adenomyosis (left panel). **(B)** the myometrium of women with (right panel) and without adenomyosis (left panel). Staining was assessed using Image J (*n* = 3 for each group) and scored on a scale of 0 (negative) to 3+ (high positive). Scale bars is 50 μm. The *p*-value was determined by a χ^2^-test.
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The WGCNA of DEGs in the myometrium of women with and without adenomyosis. Red arrow revealed the module that the differential expressed m^6^A RNA methylation regulators belongs to.
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